Tizercin (levomepromazine) coated tablets 25 mg. №50 vial

Description

Tizercin (levomepromazine) coated tablets 25 mg. №50 vial

Composition

active substance: levomepromazine maleate;

1 tablet contains levomepromazine maleate 33.80 mg, which corresponds to levomepromazine 25.00 mg;

Excipients: magnesium stearate, sodium starch glycolate (type A), povidone, microcrystalline cellulose, potato starch, lactose monohydrate, hypromellose, titanium dioxide (E 171), dimethicone.

Dosage form

Film-coated tablets.

Main physical and chemical properties: round biconvex tablets, film-coated, white, odorless.

Pharmacotherapeutic group

N05A A02.

Pharmacological properties

Tizercin® is a phenothiazine neuroleptic. Levomepromazine is an analogue of chlorpromazine with a more pronounced inhibitory effect on psychomotor activity.

By blocking dopamine receptors in the thalamus, hypothalamus, reticular and limbic systems, levomepromazine suppresses the sensory system, reduces motor activity and has a pronounced sedative effect; in addition, it has an antagonistic effect on other neurotransmitter systems (norepinephrine, serotonin, histamine, acetylcholine). Due to these properties, levomepromazine has antiemetic, antihistamine, antiadrenergic and anticholinergic effects.

Indications

The drug Tizercin is prescribed for the treatment of psychomotor agitation, psychoses, manic and depressive-paranoid states characteristic of schizophrenia, as well as reactive depression and neurotic reactions, accompanied by feelings of fear, fear, anxiety and associated with motor restlessness and sleep disturbances.
Tizercin is an active antipsychotic drug (sedative, in which there is no hypnotic effect), which has a variety of medicinal activities. Able to effectively provide a sedative response.

Contraindications

Forbidden in case of intolerance to levomepromazine. Also not used for diseases of the liver, hematopoietic organs, sclerosis, parkinsonism, cardiomyopathy, porphyria, urinary retention, angle-closure glaucoma, alcohol overdose, antidepressants.
Not recommended for chronic low blood pressure in elderly patients. It is also undesirable to use it for decompensation reactions of the cardiovascular system.

Application during pregnancy and lactation

Not assigned.

Method of administration and dosage

Tizercin is administered intramuscularly (rarely intravenously) and orally. The initial dose, which is usually administered during the period of maximum excitement, is administered intramuscularly (1-3 milliliters of Tizercin, where 1 milliliter = 0.025 grams), the maximum daily dose is 0.3-0.5 grams. When administered intravenously – no more than 0.1 grams per procedure.
Over time, the nervous system comes to a calmer state, while it is permissible to replace the i / m or i / v administration with a tablet form, which is taken by the patient orally (0.05-0.01 g per dose, and up to 0.4 grams per day). The dose is increased at a slow pace, bringing up to 0.3 grams per day. At the end of treatment, the dose is reduced to a dose of 0.1 g per day to maintain the state of the body.
When removing alcoholic psychosis, Tizercin is administered intravenously up to 0.075 g for up to 5-7 days.
In neurology, up to 0.2 grams are taken per day (with neuralgia, neuritis, shingles).
For home treatment of sleep disorders, take 1-2 tabs of Tizercin at night.

Overdose

In case of an overdose, the body reacts with a drop in blood pressure, hypothermia, impaired cardiac conduction, tachycardia, neuroleptic syndrome. Treat symptoms.

Side effects

When treating with Tizercin, the patient’s body can react with vascular hypotension, tachycardia, epileptic seizures, leukopenia, eosonophilia, dyskenesia, parkinsonism, extrapyramidal disorders, constipation, skin allergic reactions, and other side effects.